Cargando…

Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure

Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs developed for treating diabetes mellitus, improve prognosis of patients with heart failure (HF). However, the mechanisms for cardioprotection by SGLT2 inhibitors are still unclear. Mitochondrial dysfuncti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xuan, Flynn, Elizabeth R., do Carmo, Jussara M., Wang, Zhen, da Silva, Alexandre A., Mouton, Alan J., Omoto, Ana C. M., Hall, Michael E., Hall, John E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135142/ https://www.ncbi.nlm.nih.gov/pubmed/35647080 http://dx.doi.org/10.3389/fcvm.2022.859253

Ejemplares similares

Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure
por: Li, Xuan, et al.
Publicado: (2021)

Temporal changes in glucose metabolism reflect polarization in resident and monocyte-derived macrophages after myocardial infarction
por: Mouton, Alan J., et al.
Publicado: (2023)

Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview
por: Sato, Tatsuya, et al.
Publicado: (2023)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Central Nervous System Actions of Leptin Improve Cardiac Function After Ischemia–Reperfusion: Roles of Sympathetic Innervation and Sex Differences
por: Omoto, Ana C. M., et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
por: Wu, Jinchun, et al.
Publicado: (2022)

Targeting immunometabolism during cardiorenal injury: roles of conventional and alternative macrophage metabolic fuels
por: Mouton, Alan J., et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
por: Fonseca-Correa, Jorge I., et al.
Publicado: (2021)

Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
por: Rong, Xi, et al.
Publicado: (2022)

The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease
por: Neijenhuis, Ralph M. L., et al.
Publicado: (2023)

Transient receptor potential cation channel 6 contributes to kidney injury induced by diabetes and hypertension
por: Wang, Zhen, et al.
Publicado: (2022)

Sodium–glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway
por: Zhan, Xiaoping, et al.
Publicado: (2022)

Interaction of Obesity and Hypertension on Cardiac Metabolic Remodeling and Survival Following Myocardial Infarction
por: Mouton, Alan J., et al.
Publicado: (2021)

Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials
por: Gong, Chen, et al.
Publicado: (2022)

In vivo Overexpression of Electrogenic Sodium/Bicarbonate Cotransporter (NBCe1) by AAV9 Modifies the Cardiac Action Potential and the QT Interval in Mice
por: Di Mattía, Romina A., et al.
Publicado: (2022)

Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
por: Rossing, Peter, et al.
Publicado: (2022)

Leptin reverses hyperglycemia and hyperphagia in insulin deficient diabetic rats by pituitary-independent central nervous system actions
por: da Silva, Alexandre A., et al.
Publicado: (2017)

Salt overload damages the glycocalyx sodium barrier of vascular endothelium
por: Oberleithner, Hans, et al.
Publicado: (2011)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
por: Li, Runmin, et al.
Publicado: (2023)

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhou, Hufang, et al.
Publicado: (2022)

Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series
por: Giangiacomi, Francesco, et al.
Publicado: (2023)

Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
por: Xie, Yan, et al.
Publicado: (2020)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials
por: Tsai, Wan-Chuan, et al.
Publicado: (2022)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e92ol4bmg0eil288bkdarfg4k1